In a retrospective study in 159 women with at least one biospy-proven cancer, a follow-up breast-specific gamma imaging
(BSGI) study identified clinically and mammographically occult cancer in 14 of 45 lesions that were biopsied because of BSGI findings.
New studies show improved detection with techniques such as breast-specific gamma imaging
(BSGI), also referred to as molecular breast imaging; positron emission mammography (PEM), and more recently, combination PET and MR imaging.
The Dilon 6800 performs a molecular breast imaging technique called Breast-Specific Gamma Imaging
(BSGI), which can detect lesions independent of tissue density and discover very early stage cancers.
Over the last few years, the arsenal of breast screening tools has expanded to include breast magnetic resonance imaging (MRI); molecular breast imaging (MBI), or breast-specific gamma imaging
(BSGI); positron emission mammography (PEM); and, more recently, tomosynthesis.
Weinstein Imaging Associates, Pittsburgh, a leading ultrasound and breast imaging facility in Western Pennsylvania, is introducing to the region Breast-Specific Gamma Imaging
(BSGI), an innovative technology and advanced diagnostic test that helps to detect breast cancers and evaluate questionable findings on mammography or ultrasound.
Dilon Diagnostics (Newport News, VA) showcased the Dilon 6800 Gamma Camera, which performs breast-specific gamma imaging
(BSGI), also known as molecular breast imaging (MBI), and provides detection of small lesions.
Notably, the company's Breast-Specific Gamma Imaging
(BSGI) was shown to significantly contribute to the detection of malignant or high-risk lesions in patients with negative or indeterminate mammographic findings, according to results of one multicenter study.